| scholarly article | Q13442814 |
| P50 | author | Walid Heneine | Q87716498 |
| J Gerardo Garcia-Lerma | Q115633835 | ||
| P2093 | author name string | James Smith | |
| Hongwei Jia | |||
| Sunita Sharma | |||
| Chou-Pong Pau | |||
| Francis J Novembre | |||
| Amy Martin | |||
| Urvi M Parikh | |||
| Debra L Hanson | |||
| Ellen Kersh | |||
| Thomas Folks | |||
| Charles Dobard | |||
| Mian-er Cong | |||
| Ron Otten | |||
| Patricia Guenthner | |||
| P2860 | cites work | The development of vaginal microbicides for the prevention of HIV transmission | Q21092393 |
| Semen-derived amyloid fibrils drastically enhance HIV infection | Q24303668 | ||
| Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission | Q24682756 | ||
| Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir | Q28472146 | ||
| Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel | Q28473376 | ||
| Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus | Q30350983 | ||
| New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data | Q31160798 | ||
| Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings | Q33299456 | ||
| Marriage is not a safe place: heterosexual marriage and HIV-related vulnerability in Indonesia | Q33307147 | ||
| Can a topical microbicide prevent rectal HIV transmission? | Q33358267 | ||
| Whither or wither microbicides? | Q33715907 | ||
| Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3) | Q33855093 | ||
| Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. | Q35830147 | ||
| Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. | Q36540014 | ||
| HIV's vagina travelogue | Q36739040 | ||
| Microbicide drug candidates to prevent HIV infection | Q36750849 | ||
| Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission | Q36950515 | ||
| Violence against wives, sexual risk and sexually transmitted infection among Bangladeshi men | Q37136480 | ||
| Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies | Q37211585 | ||
| Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. | Q37273086 | ||
| Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial | Q37871041 | ||
| Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. | Q39165804 | ||
| Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention | Q44235156 | ||
| Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis | Q44811843 | ||
| Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates | Q45194306 | ||
| Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates | Q45412448 | ||
| Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges | Q45412452 | ||
| Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion | Q45422914 | ||
| Progesterone implants enhance SIV vaginal transmission and early virus load | Q45767734 | ||
| Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. | Q45992540 | ||
| Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy | Q46791174 | ||
| Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. | Q46837894 | ||
| Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. | Q46937577 | ||
| The condom is an 'intruder' in marriage: evidence from rural Malawi. | Q51082087 | ||
| The political economy of marriage and HIV: the ABC approach, "safe" infidelity, and managing moral risk in Uganda. | Q53190288 | ||
| Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. | Q53781127 | ||
| The inevitability of infidelity: sexual reputation, social geographies, and marital HIV risk in rural Mexico. | Q55043790 | ||
| Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates | Q64130395 | ||
| Characteristics of the menstrual cycle in nonhuman primates. IV. Timed mating in Macaca nemestrina | Q71107582 | ||
| A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team | Q71545355 | ||
| The urgent need for a vaginal microbicide in the prevention of HIV transmission | Q72518379 | ||
| Vaginal myeloperoxidase and flora in the pig-tailed macaque | Q73932824 | ||
| Men's extramarital sexuality in rural Papua New Guinea | Q80227125 | ||
| Women shoulder growing HIV/AIDS burden | Q81289898 | ||
| Development of a nonhuman primate model for Trichomonas vaginalis infection | Q83324019 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| tenofovir | Q155954 | ||
| emtricitabine | Q422604 | ||
| P304 | page(s) | 10358-10365 | |
| P577 | publication date | 2009-08-05 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine | |
| P478 | volume | 83 |
| Q35510971 | 4040 SNPs for genomic analysis in the rhesus macaque (Macaca mulatta) |
| Q37833639 | A Macaque Model for Rectal Lymphogranuloma Venereum and Non-Lymphogranuloma Venereum Chlamydia trachomatis: Impact on Rectal Simian/Human Immunodeficiency Virus Acquisition |
| Q27334384 | A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo |
| Q36294782 | A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds |
| Q36286901 | A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection |
| Q28743616 | A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel |
| Q33808638 | A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. |
| Q36359120 | A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. |
| Q33762924 | Advances in the Development of Microbicides for the Prevention of HIV Infection |
| Q27438093 | An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques |
| Q35345363 | An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques |
| Q34728884 | Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. |
| Q35572202 | Analysis of repeated low-dose challenge studies |
| Q36989915 | Animal models for microbicide safety and efficacy testing |
| Q37017688 | Animal models for microbicide studies |
| Q84774188 | Antiretroviral Therapy as HIV Prevention: Status and Prospects |
| Q35237188 | Antiretroviral-based HIV prevention strategies for women |
| Q36493442 | Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis |
| Q34078011 | Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety |
| Q46187858 | Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified? |
| Q28744206 | Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention |
| Q36018776 | Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. |
| Q35541521 | Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery |
| Q37255082 | Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. |
| Q36108441 | Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3) |
| Q37845073 | Development of a rectal sexually transmitted infection--HIV coinfection model utilizing Chlamydia trachomatis and SHIVSF162p3. |
| Q55317261 | Development of peptide inhibitors of HIV transmission. |
| Q49926142 | Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel. |
| Q28486428 | Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis |
| Q28081272 | Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery |
| Q35665851 | Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue |
| Q24629582 | Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women |
| Q37705969 | Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection |
| Q54202671 | Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal SHIV Exposures in Macaques. |
| Q35927290 | Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques |
| Q34785687 | Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention |
| Q36674475 | Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues |
| Q36111516 | Factors Important to the Prioritization and Development of Successful Topical Microbicides for HIV-1 |
| Q36032471 | Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention |
| Q30412592 | Formulation, pharmacokinetics and pharmacodynamics of topical microbicides |
| Q64128826 | Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques |
| Q35861437 | Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness |
| Q28534412 | Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis |
| Q59352978 | HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise |
| Q37438644 | HIV PrEP Trials: The Road to Success |
| Q35794988 | HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model |
| Q37888766 | HIV prevention in southern Africa: why we must reassess our strategies? |
| Q30404963 | HIV prevention transformed: the new prevention research agenda |
| Q37089865 | Humanized mouse models of HIV infection |
| Q52590774 | Identification of Unequally Represented Founder Viruses Among Tissues in Very Early SIV Rectal Transmission. |
| Q36630547 | In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward? |
| Q28472968 | In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide |
| Q27320871 | In vivo binding and retention of CD4-specific DARPin 57.2 in macaques |
| Q33598736 | Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir |
| Q34736553 | Increased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis |
| Q37218578 | Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges |
| Q35776556 | Macaque models of enhanced susceptibility to HIV. |
| Q42739568 | Microbicides & their implications in HIV prevention. |
| Q41638108 | Microbicides for preventing sexually transmitted infections: Current status and strategies for preclinical evaluation of new candidates |
| Q26999403 | Microbicides: topical prevention against HIV |
| Q36923075 | Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice |
| Q42225882 | Non-human primate models of hormonal contraception and HIV. |
| Q35345283 | Non-specific microbicide product development: then and now |
| Q36669377 | Nondaily preexposure prophylaxis for HIV prevention |
| Q41923505 | Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model |
| Q35140303 | One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates |
| Q55170368 | Optimization (central composite design) and validation of HPLC method for investigation of emtricitabine loaded poly(lactic-co-glycolic acid) nanoparticles: in vitro drug release and in vivo pharmacokinetic studies. |
| Q36409225 | Oral antiretroviral chemoprophylaxis: current status |
| Q37116845 | Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial |
| Q37713043 | Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques |
| Q53681301 | Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. |
| Q45235236 | Pharmacokinetics and in vivo biodistribution of optimized PLGA nanoparticulate drug delivery system for controlled release of emtricitabine |
| Q37258271 | Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention |
| Q34057568 | Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model |
| Q35666402 | Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques |
| Q36905431 | Pharmacologic opportunities for HIV prevention. |
| Q42232018 | Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors |
| Q36173112 | Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females |
| Q90315006 | Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline |
| Q35033732 | Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? |
| Q35941336 | Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide |
| Q35717688 | Preexposure prophylaxis for HIV prevention |
| Q26825042 | Preexposure prophylaxis for HIV prevention: where have we been and where are we going? |
| Q26828445 | Preventing HIV infection: pre-exposure and postexposure prophylaxis |
| Q34548621 | Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities |
| Q34506545 | Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen |
| Q40062702 | Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice |
| Q36306935 | Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir |
| Q55514511 | Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. |
| Q33900344 | Rapid dissemination of SIV follows multisite entry after rectal inoculation. |
| Q27311591 | Rectal application of a highly osmolar personal lubricant in a macaque model induces acute cytotoxicity but does not increase risk of SHIV infection |
| Q36284595 | Relationship of Estimated SHIV Acquisition Time Points During the Menstrual Cycle and Thinning of Vaginal Epithelial Layers in Pigtail Macaques |
| Q35798274 | Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses |
| Q37803317 | Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective |
| Q28742018 | SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses |
| Q35806225 | Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings |
| Q37023114 | Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis |
| Q36364164 | Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques |
| Q36259499 | Short Communication: Practical Experience with Analysis and Design of Repeat Low-Dose SHIVSF162P3 Exposure Studies in Female Pigtail Macaques with Varying Susceptibility During Menstrual Cycling |
| Q34399723 | Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures |
| Q34399737 | Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides |
| Q35689332 | Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring |
| Q30858811 | Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial |
| Q37932048 | Specific microbicides in the prevention of HIV infection |
| Q28834077 | Stimulus-responsive hydrogels: Theory, modern advances, and applications. |
| Q36937885 | Susceptibility to repeated, low-dose, rectal SHIVSF162P3 challenge is independent of TRIM5 genotype in rhesus macaques |
| Q37061624 | Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis |
| Q28477909 | T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis |
| Q40191155 | Tackling HIV and AIDS: contributions by non-human primate models |
| Q33518390 | Targeting Trojan Horse leukocytes for HIV prevention |
| Q90210146 | Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial |
| Q22242692 | Tenofovir-based pre-exposure prophylaxis for HIV prevention |
| Q30621914 | Tenofovir-based preexposure prophylaxis for HIV infection among African women |
| Q38009758 | Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? |
| Q37511883 | The Promise of Antiretrovirals for HIV Prevention |
| Q35903632 | The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention |
| Q34982693 | The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques |
| Q36359133 | The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection |
| Q35760180 | The use of preexposure treatments for HIV prophylaxis |
| Q28550108 | Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures |
| Q35031133 | Topical prophylaxis for HIV prevention in women: becoming a reality |
| Q36816377 | Use of antiretrovirals for HIV prevention: what do we know and what don't we know? |
| Q64899382 | Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. |
| Q45356336 | Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. |
| Q36032459 | pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission |
Search more.